ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
Please provide your email address to receive an email when new articles are posted on . At week 96, treatment led to significant reductions in all exploratory MS-related biomarkers. Additional ...
The MarketWatch News Department was not involved in the creation of this content. -- ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback